Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus

Journal of Diabetes

Volumn 7, Issue 6, 2015, Pages 762-773

  He, Binbin ^a   Li, Xia ^a   Yu, Haibo ^a   Zhou, Zhiguang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Immune cells; Regulatory T cell; Stem cell; Type 1 diabetes mellitus; Umbilical cord blood

Indexed keywords

INSULIN;

AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DAMAGE; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETOGENESIS; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETREATMENT; REVIEW; THERAPY EFFECT; ANIMAL; AUTOIMMUNITY; AUTOTRANSPLANTATION; BLOOD; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNITY; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84945496503     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12286     Document Type: Review

References (111)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
2. Burton AR, Vincent E, Arnold PY etal. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes. 2008; 57: 1321-1330.
3. Han B, Serra P, Yamanouchi J etal. Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest. 2005; 115: 1879-1887.
4. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009; 155: 173-181.
5. Graham KL, Sutherland RM, Mannering SI etal. Pathogenic mechanisms in type 1 diabetes: The islet is both target and driver of disease. Rev Diabet Stud. 2012; 9: 148-168.
6. Atkinson MA. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med. 2012; 2: a007641.
7. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010; 464: 1293-1300.
8. Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med. 2012; 12: 1261-1272.
9. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1yr of cyclosporin treatment with enhanced insulin secretion. Diabetes. 1988; 37: 1574-1582.
10. Ludvigsson J, Faresjo M, Hjorth M etal. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008; 359: 1909-1920.
11. Raz I, Avron A, Tamir M etal. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: Extension of a randomized, double-blind, Phase II trial. Diabetes Metab Res Rev. 2007; 23: 292-298.
12. Herold KC, Gitelman SE, Masharani U etal. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005; 54: 1763-1769.
13. Keymeulen B, Walter M, Mathieu C etal. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010; 53: 614-623.
14. Orban T, Bundy B, Becker DJ etal. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet. 2011; 378: 412-419.
15. Pescovitz MD, Greenbaum CJ, Bundy B etal. B-lymphocyte depletion with rituximab and beta-cell function: Two-year results. Diabetes Care. 2014; 37: 453-459.
16. Haller MJ, Wasserfall CH, McGrail KM etal. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care. 2009; 32: 2041-2046.
17. Haller MJ, Wasserfall CH, Hulme MA etal. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care. 2011; 34: 2567-2569.
18. Giannopoulou EZ, Puff R, Beyerlein A etal. Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: A non-randomized, controlled trial. Pediatr Diabetes. 2014; 15: 100-109.
19. Ilic D, Miere CLazic E. Umbilical cord blood stem cells: Clinical trials in non-hematological disorders. Br Med Bull. 2012; 102: 43-57.
20. Gluckman E. History of cord blood transplantation. Bone Marrow Transplant. 2009; 44: 621-626.
21. Gluckman E, Broxmeyer HA, Auerbach AD etal. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989; 321: 1174-1178.
22. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995; 346: 214-219.
23. Lee YH. Clinical utilization of cord blood over human health: Experience of stem cell transplantation and cell therapy using cord blood in Korea. Korean J Pediatr. 2014; 57: 110-116.
24. Godfrey WR, Spoden DJ, Ge YG etal. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood. 2005; 105: 750-758.
25. Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol. 2011; 79: 112-126.
26. Prabakar KR, Dominguez-Bendala J, Molano RD etal. Generation of glucose-responsive, insulin-producing cells from human umbilical cord blood-derived mesenchymal stem cells. Cell Transplant. 2012; 21: 1321-1339.
27. Yoshida S, Ishikawa F, Kawano N etal. Human cord blood-derived cells generate insulin-producing cells in vivo. Stem Cells. 2005; 23: 1409-1416.
28. Denner L, Bodenburg Y, Zhao JG etal. Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin. Cell Prolif. 2007; 40: 367-380.
29. Haller MJ, Wasserfall CH, Hulme MA etal. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant. 2013; 19: 1126-1129.
30. Zhao Y, Jiang Z, Zhao T etal. Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 2012; 10: 3.
31. Voltarelli JC, Couri CE, Stracieri AB etal. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007; 297: 1568-1576.
32. Voltarelli JC, Couri CE, Stracieri AB etal. Autologous hematopoietic stem cell transplantation for type 1 diabetes. Ann N Y Acad Sci. 2008; 1150: 220-229.
33. Couri CE, Oliveira MC, Stracieri AB etal. C-Peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009; 301: 1573-1579.
34. Snarski E, Milczarczyk A, Torosian T etal. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 2011; 46: 562-566.
35. Li L, Shen S, Ouyang J etal. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves beta-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 2012; 97: 1729-1736.
36. Zhang X, Ye L, Hu J etal. Acute response of peripheral blood cell to autologous hematopoietic stem cell transplantation in type 1 diabetic patient. PLoS ONE. 2012; 7: e31887.
37. - regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care. 2012; 35: 1817-1820.
38. - regulatory T cells prolongs survival of pancreatic islets: Results of one year follow-up. Clin Immunol. 2014; 153: 23-30.
39. Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2014; 64: 587-592.
40. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev. 2012; 12: 127-136.
41. Miller MR, Seifert J, Szabo NJ, Clare-Salzler M, Rewers M, Norris JM. Erythrocyte membrane fatty acid content in infants consuming formulas supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA): An observational study. Matern Child Nutr. 2010; 6: 338-346.
42. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012; 12: 191-200.
43. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014; 14: 154-165.
44. Peters JH, Preijers FW, Woestenenk R, Hilbrands LB, Koenen HJ, Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS ONE. 2008; 3: E3161.
45. + T cells. Clin Immunol. 2005; 115: 10-18.
46. + immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000; 12: 431-440.
47. + regulatory T cell: A jack of all trades, master of regulation. Nat Immunol. 2008; 9: 239-244.
48. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155: 1151-1164.
49. + T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA. 2003; 100: 10-878.
50. + regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci USA. 2004; 101 (Suppl. 2): 14580-14585.
51. Weber SE, Harbertson J, Godebu E etal. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol. 2006; 176: 4730-4739.
52. Skyler JS, Krischer JP, Wolfsdorf J etal. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care. 2005; 28: 1068-1076.
53. Sherry N, Hagopian W, Ludvigsson J etal. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011; 378: 487-497.
54. Orban T, Bundy B, Becker DJ etal. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year after cessation of treatment. Diabetes Care. 2014; 37: 1069-1075.
55. Agardh CD, Cilio CM, Lethagen A etal. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications. 2005; 19: 238-246.
56. Putnam AL, Brusko TM, Lee MR etal. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009; 58: 652-662.
57. +CD25(high) T cells become functional regulatory T cells upon antigen encounter. PLoS ONE. 2012; 7: e29355.
58. Torelli GF, Maggio R, Peragine N etal. Functional analysis and gene expression profile of umbilical cord blood regulatory T cells. Ann Hematol. 2012; 91: 155-161.
59. Fan H, Yang J, Hao J etal. Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood. Immunology. 2012; 136: 218-230.
60. + regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. Transfusion. 2012; 52: 1333-1347.
61. Brunstein CG, Miller JS, Cao Q etal. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood. 2011; 117: 1061-1070.
62. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007; 7: 585-598.
63. Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008; 36: 710-715.
64. Biazar E. Use of umbilical cord and cord blood-derived stem cells for tissue repair and regeneration. Expert Opin Biol Ther. 2014; 14: 301-310.
65. Behzad-Behbahani A, Pouransari R, Tabei SZ etal. Risk of viral transmission via bone marrow progenitor cells versus umbilical cord blood hematopoietic stem cells in bone marrow transplantation. Transplant Proc. 2005; 37: 3211-3212.
66. Behzad-Behbahani A, Entezam M, Mojiri A etal. Incidence of human herpes virus-6 and human cytomegalovirus infections in donated bone marrow and umbilical cord blood hematopoietic stem cells. Indian J Med Microbiol. 2008; 26: 252-255.
67. Ende N, Chen R, Mack R. NOD/LtJ type I diabetes in mice and the effect of stem cells (Berashis) derived from human umbilical cord blood. J Med. 2002; 33: 181-187.
68. Ende N, Chen R, Reddi AS. Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochem Biophys Res Commun. 2004; 325: 665-669.
69. Wang M, Yang Y, Yang D etal. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology. 2009; 126: 220-232.
70. Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev. 2014; 23: 1258-1265.
71. Zhao Y, Huang Z, Qi M, Lazzarini P, Mazzone T. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunol Lett. 2007; 108: 78-87.
72. van den Berk LC, Jansen BJ, Snowden S etal. Cord blood mesenchymal stem cells suppress DC-T cell proliferation via prostaglandin B2. Stem Cells Dev. 2014; 23: 1582-1593.
73. + regulatory T cells from cord blood hematopoietic progenitor cells. J Leukoc Biol. 2009; 85: 445-451.
74. Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA. Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS ONE. 2009; 4: e4226.
75. Zhao Y, Mazzone T. Human cord blood stem cells and the journey to a cure for type 1 diabetes. Autoimmun Rev. 2010; 10: 103-107.
76. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA. 1992; 89: 2804-2808.
77. Ivanovs A, Rybtsov S, Anderson RA, Turner ML, Medvinsky A. Identification of the niche and phenotype of the first human hematopoietic stem cells. Stem Cell Reports. 2014; 2: 449-456.
78. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure? Blood. 2002; 99: 768-784.
79. + progenitor cells: Evidence for a deletion-based mechanism mediated by TNF-alpha. Blood. 2005; 105: 2585-2593.
80. Kared H, Leforban B, Montandon R etal. Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood. 2008; 112: 2575-2578.
81. Atkins HL, Muraro PA, van Laar JM, Pavletic SZ. Autologous hematopoietic stem cell transplantation for autoimmune disease-is it now ready for prime time? Biol Blood Marrow Transplant. 2012; 18 (Suppl.) S177-183.
82. Beilhack GF, Scheffold YC, Weissman IL etal. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes. 2003; 52: 59-68.
83. Kang EM, Zickler PP, Burns S etal. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol. 2005; 33: 699-705.
84. Verda L, Kim DA, Ikehara S etal. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells. 2008; 26: 381-386.
85. Gu W, Hu J, Wang W etal. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care. 2012; 35: 1413-1419.
86. Theunissen K, Verfaillie CM. A multifactorial analysis of umbilical cord blood, adult bone marrow and mobilized peripheral blood progenitors using the improved ML-IC assay. Exp Hematol. 2005; 33: 165-172.
87. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: The first 25 years and beyond. Blood. 2013; 122: 491-498.
88. + positive cells expanded from umbilical cord blood expressing PDX-1 and markers of pluripotency. Cell Biol Int. 2010; 34: 783-790.
89. + cells enhances their engraftment of NSG mice. Blood Cells Mol Dis. 2011; 46: 318-320.
90. Bari S, Chu PP, Lim A etal. Protective role of functionalized single walled carbon nanotubes enhance ex vivo expansion of hematopoietic stem and progenitor cells in human umbilical cord blood. Nanomedicine. 2013; 9: 1304-1316.
91. Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004; 305: 1000-1003.
92. Khurana S, Margamuljana L, Joseph C, Schouteden S, Buckley SM, Verfaillie CM. Glypican-3-mediated inhibition of CD26 by TFPI: A novel mechanism in hematopoietic stem cell homing and maintenance. Blood. 2013; 121: 2587-2595.
93. Duncanson S, Sambanis A. Dual factor delivery of CXCL12 and exendin-4 for improved survival and function of encapsulated beta cells under hypoxic conditions. Biotechnol Bioeng. 2013; 110: 2292-2300.
94. Voltarelli JC, Couri CE, Rodrigues MC etal. Stem cell therapies for type 1 diabetes mellitus. Indian J Exp Biol. 2011; 49: 395-400.
95. Dominici M, Le Blanc K, Mueller I etal. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8: 315-317.
96. Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: State of the art. Int J Clin Exp Med. 2010; 3: 248-269.
97. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: A potential therapeutic strategy for type 1 diabetes. Diabetes. 2008; 57: 1759-1767.
98. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014; 21: 216-225.
99. Davis NE, Hamilton D, Fontaine MJ. Harnessing the immunomodulatory and tissue repair properties of mesenchymal stem cells to restore beta cell function. Curr Diab Rep. 2012; 12: 612-622.
100. Bassi EJ, Moraes-Vieira PM, Moreira-Sa CS etal. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes. 2012; 61: 2534-2545.
101. Keating A. Mesenchymal stromal cells: New directions. Cell Stem Cell. 2012; 10: 709-716.
102. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24: 1294-1301.
103. Jin HJ, Bae YK, Kim M etal. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci. 2013; 14: 17986-18001.
104. Gabr MM, Zakaria MM, Refaie AF etal. Generation of insulin-producing cells from human bone marrow-derived mesenchymal stem cells: Comparison of three differentiation protocols. Biomed Res Int. 2014; 2014: 832736.
105. Gao F, Wu DQ, Hu YH etal. In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Transl Res. 2008; 151: 293-302.
106. Wang HS, Shyu JF, Shen WS etal. Transplantation of insulin-producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice. Cell Transplant. 2011; 20: 455-466.
107. Tsai PJ, Wang HS, Shyr YM etal. Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats. J Biomed Sci. 2012; 19: 47.
108. Zhao Y, Wang H, Mazzone T. Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp Cell Res. 2006; 312: 2454-2464.
109. Zhao Y, Lin B, Dingeldein M, Guo C, Hwang D, Holterman MJ. New type of human blood stem cell: A double-edged sword for the treatment of type 1 diabetes. Transl Res. 2010; 155: 211-216.
110. Zhao Y. Stem cell educator therapy and induction of immune balance. Curr Diab Rep. 2012; 12: 517-523.
111. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A etal. Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med. 2012; 12: 574-591.